Theresa Ann Deisher PhD

Dr. Theresa Deisher’s career has focused on discovering and developing new therapies for grievous human illness. Dr. Deisher obtained her Ph.D. in Molecular and Cellular Physiology from Stanford University and has spent over 19 years in commercial biotechnology, working with such illustrious companies as Genentech, Repligen, ZymoGenetics, Immunex and Amgen, prior to founding AVM Biotechnology and Sound Choice Pharmaceutical Institute. AVM Biotechnology is the marquee pro-life biotech company worldwide, certifying that it does not use morally illicit material in any process.

Dr. Deisher is an inventor on 23 issued US patents, and her discoveries have led to clinical trials of FGF18 for osteoarthritis and cartilage repair, and for Factor XIII for surgical bleeding. Dr. Deisher was the first person to discover adult cardiac-derived stem cells and has been a champion of adult stem cell research, both professionally and privately, for two decades. Dr. Deisher is a plaintiff in the US federal lawsuit to prohibit the use of federal taxpayer dollars for embryo-destructive research.